Bank of Montreal Can Increases Stake in Solventum Co. (NYSE:SOLV)

Bank of Montreal Can boosted its holdings in Solventum Co. (NYSE:SOLV) by 15.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 182,748 shares of the company’s stock after buying an additional 25,002 shares during the quarter. Bank of Montreal Can’s holdings in Solventum were worth $12,348,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. Tokio Marine Asset Management Co. Ltd. boosted its position in shares of Solventum by 4.2% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company’s stock worth $346,000 after buying an additional 200 shares in the last quarter. National Bank of Canada FI boosted its stake in shares of Solventum by 4.0% in the second quarter. National Bank of Canada FI now owns 6,093 shares of the company’s stock valued at $314,000 after purchasing an additional 236 shares during the period. IVC Wealth Advisors LLC lifted its stake in shares of Solventum by 5.0% in the third quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company’s stock worth $464,000 after acquiring an additional 318 shares in the last quarter. KKM Financial LLC boosted its stake in shares of Solventum by 7.9% during the 3rd quarter. KKM Financial LLC now owns 4,367 shares of the company’s stock valued at $304,000 after buying an additional 319 shares during the last quarter. Finally, Copeland Capital Management LLC acquired a new stake in shares of Solventum in the 3rd quarter valued at about $26,000.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on SOLV shares. Morgan Stanley increased their price objective on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. BTIG Research started coverage on Solventum in a research note on Thursday, September 5th. They issued a “neutral” rating for the company. Stifel Nicolaus began coverage on shares of Solventum in a research report on Tuesday, October 8th. They set a “buy” rating and a $82.00 price objective on the stock. Piper Sandler upped their price target on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. Finally, Wolfe Research started coverage on Solventum in a report on Thursday, September 26th. They issued a “peer perform” rating on the stock. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $68.00.

Solventum Price Performance

NYSE SOLV opened at $71.51 on Monday. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05. The business has a fifty day simple moving average of $70.55 and a 200 day simple moving average of $62.58. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.